Q4 2025 13F Holders as of 31 Dec 2025
-
Type / Class
-
Equity / Common Stock,$0.001 par value per share
-
Shares outstanding
-
72,096,078
-
Total 13F shares
-
40,517,312
-
Share change
-
-12,771,099
-
Total reported value
-
$54,747,323
-
Price per share
-
$1.35
-
Number of holders
-
85
-
Value change
-
-$19,981,164
-
Number of buys
-
32
-
Number of sells
-
46
Institutional Holders of Zentalis Pharmaceuticals, Inc. - Common Stock,$0.001 par value per share (ZNTL) as of Q4 2025
As of 31 Dec 2025,
Zentalis Pharmaceuticals, Inc. - Common Stock,$0.001 par value per share (ZNTL) was held by
85 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
40,517,312 shares.
The largest 10 holders included
5AM Venture Management, LLC, RENAISSANCE TECHNOLOGIES LLC, VANGUARD GROUP INC, ACADIAN ASSET MANAGEMENT LLC, CITADEL ADVISORS LLC, D. E. Shaw & Co., Inc., TWO SIGMA ADVISERS, LP, TWO SIGMA INVESTMENTS, LP, Opaleye Management Inc., and BANK OF AMERICA CORP /DE/.
This page lists
85
institutional shareholders reporting positions in this security
for the Q4 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.